In a progressive move towards transforming the healthcare landscape, Avalon GloboCare Corp. (NASDAQ: ALBT), a trailblazing developer of innovative cell-based technology, cellular therapy, and precision diagnostics, has recently extended its exclusive distribution agreement with Qi Diagnostics Limited. This collaboration aims to bring the revolutionary KetoAir breathalyzer device and its cutting-edge accessories, both current and future models, to key regions including North America, South America, the United Kingdom, and the European Union.
The extension of this alliance between Avalon GloboCare and Qi Diagnostics holds immense promise for the advancement of healthcare solutions worldwide, leveraging state-of-the-art technology to provide accurate and efficient diagnostic capabilities. The KetoAir breathalyzer device, alongside its AI-enabled software, represents a groundbreaking breakthrough in the field of precision diagnostics, offering enhanced accuracy, ease of use, and affordability.
With the extended agreement, Avalon GloboCare has solidified its position as the exclusive distributor of the KetoAir breathalyzer device and its associated accessories in the aforementioned regions. This strategic partnership not only reinforces Avalon’s commitment to driving innovation in cellular therapy but also expands its reach to healthcare providers and individuals seeking state-of-the-art diagnostic solutions.
The KetoAir breathalyzer device utilizes innovative technology to detect a wide range of analytes, enabling comprehensive screening and analysis of multiple health conditions. It represents a valuable tool for doctors, researchers, and healthcare practitioners, facilitating early detection and monitoring of various diseases. By harnessing the power of breath analysis, this device offers a non-invasive and convenient method of diagnosis, eliminating the need for invasive procedures and complex laboratory testing.
One of the standout features of the KetoAir breathalyzer device is its integration with AI-enabled software, providing real-time analysis and intelligent insights. This cutting-edge software leverages machine learning algorithms to analyze breath samples, allowing for prompt and accurate identification of potential health issues. By combining advanced technology with ease of use, the KetoAir breathalyzer device presents a transformative solution in the field of diagnostics, delivering personalized and precise healthcare for individuals worldwide.
The distribution agreement extension between Avalon GloboCare and Qi Diagnostics signals an important milestone in the advancement of healthcare technology, utilizing the power of cellular therapy and precision diagnostics to enhance patient outcomes. With exclusive distribution rights in North America, South America, the United Kingdom, and the European Union, Avalon GloboCare is poised to revolutionize the healthcare industry by providing access to the latest tools and technologies that improve lives.
As healthcare providers and individuals navigate the challenges posed by various health conditions, the KetoAir breathalyzer device and its AI-enabled software offer a breakthrough solution that empowers early detection, personalized treatment, and efficient monitoring. Transforming the diagnostic landscape, Avalon GloboCare and Qi Diagnostics are reshaping the future of healthcare by delivering high-quality and cost-effective solutions for improved patient care.
By joining forces with Qi Diagnostics, Avalon GloboCare continues its mission to drive innovation and progress in cellular therapy and precision diagnostics. Through this exclusive distribution agreement, healthcare professionals and individuals across North America, South America, the United Kingdom, and the European Union will soon have access to the KetoAir breathalyzer device, bringing forth a new era in diagnostic accuracy and efficiency.
Comments